Clinical Evidence
Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

Setting: Atrium Health Wake Forest Baptist Intensive Care Units
Objective
To compare the effectiveness of EndoTool IV in reducing hospital LOS and hypoglycemia rates compared to standard insulin infusion protocols.
Setting
Atrium Health Wake Forest Baptist Intensive Care Units
Results
- Significant Patient Population: The study analyzed data from 354 patients on the Endotool IV dashboard, with 53.3% treated using EndoTool IV and 46.6% receiving standard treatment.
- Reduced Length of Stay: Patients treated with EndoTool IV had a shorter hospital stay (3.95 days) compared to those with standard insulin infusion (4.40 days), resulting in a cost difference of $12,000,000 between the two groups.
- Enhanced Safety: EndoTool IV demonstrated lower number of hypoglycemia and severe hypoglycemia events, ensuring safer management of glucose levels compared to standard insulin infusion.
Conclusions
- Reduced Length of Stay: Patients treated with EndoTool IV experience shorter hospital stays, allowing for quicker recovery and increased bed availability.
- Enhanced Patient Safety: EndoTool IV minimizes hypoglycemia and severe hypoglycemia events through a gentler approach to achieving glycemic targets, ensuring safer insulin titration.
- Significant Cost Savings: By reducing hospital length of stay and lowering hypoglycemia events, EndoTool IV delivers substantial cost savings for healthcare systems.
References
Authors
M. McKnight, C. Price, C. Usoh, G.Russell, R. Bundy, J. Aloi
Source
American Association of Clinical Endocrinology (AACE) Annual Meeting
Year
2024
Related posts

Clinical Evidence
Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ
Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ
Temple Health, a 3-hospital academic system was experiencing high rates of hypoglycemia due to reliance on sliding scale insulin (SSI). To improve safety and align with ADA guidelines, the hospital implemented EndoTool SubQ, a patient-specific insulin dosing software the supports four dosing protocols, including basal-bolus-correction (BBC).

Clinical Evidence
How Corewell Health Reduced LOS for DKA Patients, Slashing Costs by Almost $1M
How Corewell Health Reduced LOS for DKA Patients, Slashing Costs by Almost $1M
The objective of this study was to evaluate the impact of EndoTool IV insulin dosing software on mortality, length of stay, readmission rates, and cost of care for patients treated for Diabetic Ketoacidosis (DKA) at Corewell Health West.

Clinical Evidence
Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment
Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment
The objective of this study was to evaluate the impact of renal insufficiency on hypoglycemia rates in patients treated for Diabetic Ketoacidosis (DKA) utilizing a computerized insulin dosing algorithm.
Get in Touch
Ready to get started?
Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.
"*" indicates required fields